Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes

• Status: Completed
• Trial end date: 2003-11-26
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Asia. The aim of this trial is to investigate the efficacy of biphasic insulin aspart 30 on postprandial glycaemic control.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Biphasic Insulins; Insulin; Insulin Aspart; Insulin aspart, insulin aspart protamine drug combination 30:70; Insulin degludec, insulin aspart drug combination; Insulin, Globin Zinc; Insulin, Isophane; Insulin, Long-Acting

Criteria

Inclusion Criteria:

• Type 1 or 2 diabetes for at least 3 months

• Stabilised on current treatment with premixed human insulin for at least 4 weeks

• Body mass index (BMI) between 18-40 kg/m2

• HbA1c below 13.0%

• Able and willing to perform self-blood glucose monitoring

Exclusion Criteria:

• The receipt of any investigational drug within the last three months prior to this trial

• Has a history of drug abuse or alcohol dependence within the last 5 years

• Active proliferative retinopathy requiring laser or surgical intervention within the last year

• Recurrent major hypoglycaemia as judged by the Investigator

• Known or suspected allergy to trial product or related product